Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-hodgkin lymphoma

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2493-2501

  Gerecitano, John ^a   Portlock, Carol ^a   Hamlin, Paul ^a   Moskowitz, Craig H ^a   Noy, Ariela ^a   Straus, David ^a   Schulman, Philip ^a   Dumitrescu, Otilia ^a   Sarasohn, Debra ^a   Pappanicholaou, Jennifer ^a   Iasonos, Alexia ^a   Zhang, Zhigang ^a   Mo, Qianxing ^a   Horanlli, Endri ^a   Rojas, Celeste N ^b   Zelenetz, Andrew D ^a   O'Connor, Owen A ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; BORTEZOMIB; CYCLOPHOSPHAMIDE; PLATINUM COMPLEX; PREDNISONE; PURINE DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ADULT; AGED; ALLERGIC RHINITIS; ANEMIA; ANXIETY; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER RELAPSE; CHILL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FECES INCONTINENCE; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOXIA; INFECTION; INSOMNIA; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RADIOIMMUNOTHERAPY; RIGOR; SENSORY NEUROPATHY; SIDE EFFECT; SKIN BRUISING; SWEATING; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; VOMITING; XEROSTOMIA;

ANEMIA; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CYCLOPHOSPHAMIDE; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FATIGUE; FEMALE; FEVER; FOLLOW-UP STUDIES; HUMANS; LEUKOPENIA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NAUSEA; PREDNISONE; PYRAZINES; RECURRENCE; TREATMENT OUTCOME;

EID: 79954614811     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1498     Document Type: Article

References (25)

1. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019-26. (Pubitemid 46224008)
2. Tan D, Rosenberg SA, Levy R, Lavori P, Tibshirani R, Hoppe RT, et al. Survival in follicular lymphoma: The Stanford Experience, 1960-2003. Blood (ASH Annu Meeting Abstr) 2007;110:3428.
3. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511-8.
4. Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995;13:140-7.
5. Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA, et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol 2008;19:1327-30. (Pubitemid 351911966)
6. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687-93.
7. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-23.
8. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676-84. (Pubitemid 46237441)
9. Goy A, Bernstein S, Kahl B, Epner E, Leonard JP, Stadtmauer E, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma (MCL): preliminary results of the PINNACLE study. J Clin Oncol 2005;23 Suppl: 6563.
10. Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006;24:2105-12. (Pubitemid 46622122)
11. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867-74. (Pubitemid 46655613)
12. Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009;20:520-5.
13. de Vos S, Dakhil S, McLaughlin P, Saleh M, Belt R, Flowers C, et al. Bortezomib plus rituximab in patients with indolent non-Hodgkin's lymphoma (NHL): a phase 2 study (abstract). Blood 2005;106:17.
14. Gerecitano J, Portlock C, Moskowitz C, Hamlin P, Straus D, Zelenetz AD, et al. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. Br J Haematol 2009;146:652-5.
15. de Vos S, Goy A, Dakhil SR, Saleh MN, McLaughlin P, Belt R, et al. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J Clin Oncol 2009;27:5023-30.
16. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI sponsored International Working Group. J Clin Oncol 1999;17:1244-53. (Pubitemid 29162950)
17. Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007;138:330-7. (Pubitemid 47035389)
18. Head KA. Peripheral neuropathy: pathogenic mechanisms and alternative therapies. Altern Med Rev 2006;11:294-329. (Pubitemid 46037130)
19. Sehn LH, Macdonald DA, Rubin SH, Rubinger M, Imrie KR, Chapman J-AW, et al. Tolerability and efficacy of bortezomib added to CVP-R for previously untreated advanced stage follicular lymphoma: interim analysis of a phase II study by the NCIC Clinical Trials Group. Blood (ASH Annu Meeting Abstr) 2008;112:1576.
20. Leonard J, Furman R, Cheung Y-KK, Vose J, Glynn P, Ruan J, et al. CHOP-R +bortezomib as initial therapy for diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 2007;25 Suppl: 8031.
21. San Miguel J, Blade J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 2006;11:51-61. (Pubitemid 43152686)
22. Stern JL, di Carlo MW, Schuster MW, Shore TB, Harpel JG, Pearse R, et al. Bortezomib added to the standard mobilization regimen of GCSF and high-dose cyclophosphamide is a safe and effective combination for a high yield stem cell collection while promoting further tumor mass reduction in myeloma. Blood 2006;108.
23. Barr PM, Fu P, Lazarus HM, Horvath N, Gerson SL, Koc ON, et al. Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. Br J Haematol 2009;147:89-96.
24. Matous J, Letzer J, Rosen P, Noga F, Fowler N, Smith SM, et al. Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): dose-finding results of the VERTICAL study. J Clin Oncol 2009;27:abstr 8550.
25. Agathocleous A. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia. Br J Haematol 2010;151:346-53.